The primary objective of the Inflammatory Bowel Disease (IBD) and Translational Gastroenterology group at Örebro University is to identify markers that can enhance clinical decision-making and elucidate the pathophysiological mechanisms underlying these markers or marker signatures. To accomplish this objective, our group employs a multifaceted approach involving the analysis of unique clinical cohorts and multi-omic molecular profiling to improve the identification of predictive, diagnostic, prognostic, and therapeutic biomarkers. Our research efforts involve a broad range of activities and span all the way from large-scale epidemiological investigations to mechanistic investigations, all aimed towards the objective of clinical translation. These activities are facilitated through collaborative partnerships with national and international research groups as well as patient organisations.
Role within miGut-Health
As a partner in work package 1 in the miGut-Health project, ORU is participating in the coordination and harmonisation of prospective clinical cohort studies, where ORU is responsible for the Swedish IBD twin cohort and Swedish preclinical cohorts of individuals who later in life are diagnosed with IBD. Subsequently, ORU will contribute to identifying predictive, diagnostic, and prognostic markers through multi-omic characterisation methodologies, such as proteome and exposome-metabolome analyses.